NATCO Pharma Limited

Informe acción NSEI:NATCOPHARM

Capitalización de mercado: ₹184.1b

Dividendos de NATCO Pharma

Dividendo controles de criterios 4/6

NATCO Pharma es una empresa que paga dividendos con una rentabilidad actual de 0.93% que está bien cubierta por los beneficios.

Información clave

0.9%

Rentabilidad por dividendo

13%

Ratio de pago

Rentabilidad media de la industria0.7%
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónn/a
Beneficios por acción₹71.34
Rentabilidad por dividendo prevista a 3 años1.1%

Últimas actualizaciones de dividendos

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12
NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Recent updates

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Apr 03
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18
NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17
NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12
Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12
NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20
NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20
Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12
NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02
Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 22
NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year

Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Feb 16
Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden

Nov 30
Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 24
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well

Mar 22
These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well

Should NATCO Pharma Limited (NSE:NATCOPHARM) Be Part Of Your Dividend Portfolio?

Mar 04
Should NATCO Pharma Limited (NSE:NATCOPHARM) Be Part Of Your Dividend Portfolio?

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: El pago de dividendos de NATCOPHARM ha sido volátil en los últimos 10 años.

Dividendo creciente: El pago de dividendos de NATCOPHARM ha aumentado en los últimos 10 años.


Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de NATCO Pharma vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de NATCOPHARM con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (NATCOPHARM)0.9%
Suelo de mercado 25% (IN)0.3%
Techo de mercado 25% (IN)1.2%
Media de la industria (Pharmaceuticals)0.7%
Previsión de analistas en 3 años (NATCOPHARM)1.1%

Dividendo destacado: El dividendo de NATCOPHARM(0.93%) es más alto que el 25% inferior de los pagadores de dividendos del mercado Indian (0.27%).

Alto dividendo: El (0.93%) del dividendo de NATCOPHARM es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Indian (1.19%).


Pago de beneficios a los accionistas

Cobertura de los beneficios: Con su bajo ratio de pago (13.4%), los pagos de dividendos de NATCOPHARM están totalmente cubiertos por los beneficios.


Pago en efectivo a los accionistas

Cobertura de flujo de caja: Con su razonablemente bajo ratio de pago en efectivo (32.5%), los pagos de dividendos de NATCOPHARM están bien cubiertos por los flujos de caja.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target